| Entries |
| Document | Title | Date |
|---|
| 20080286372 | THERAPEUTIC COMPOSITIONS FOR TARGETED VESSEL DELIVERY - Methods for treating a vascular disease by delivering therapeutic compositions with enhanced endothelium targeting are disclosed. | 11-20-2008 |
| 20090061007 | Pharmaceutical preparation - A pharmaceutical preparation comprises nano-level particles (nanospheres) of a biocompatible polymer having, as held on their surfaces, an NFκB decoy capable of binding to NFκB to inhibit its activity. With penetration of the nanoparticles inside cells, the NFκB decoy may be delivered to an affected site and the NFκB decoy may be released from the surfaces of the nanoparticles and may be thereby efficiently and specifically introduced into the affected site. | 03-05-2009 |
| 20090068278 | USE OF FREE RADICAL SCAVENGERS FOR PROTECTING AND TREATING SKIN AND HAIR DAMAGES CAUSED BY CHEMOTHERAPY - The present invention relates to the use of one or more free radical scavengers as prophylactically or therapeutically effective substances and microparticles having an average particle size ranging from 5 to 200 μm for the preparation of a topical pharmaceutical composition for the protection or treatment of skin or hair damages caused by chemotherapeutic treatment. | 03-12-2009 |
| 20090110740 | Materials and Methods for Modulating Metabolism - The subject invention provides materials and methods for modulating a variety of biological factors to treat biological conditions associated with the factors. In one embodiment of the invention, a cysteamine compound is administered to a patient to treat hypercholesterolemia and/or complications associated with hypercholesterolemia. In another embodiment, a cysteamine compound is administered to a patient to prevent the onset of diabetes in an at-risk patient and/or treat or prevent the onset of diabetes-associated complications. | 04-30-2009 |
| 20090117195 | Hydrophilic Particles Based on Cationic Chitosan Derivatives - The present invention provides new nanoparticles and microparticles of hydrophilic character, prepared out of a cationic chitosan derivative and a polyanionic polymer. | 05-07-2009 |
| 20090142404 | PHARMACEUTICAL DOSAGE FORMS COMPRISING A LOW-SOLUBILITY DRUG AND A POLYMER - A dosage form comprises a low-solubility drug, and a precipitation-inhibiting polymer. The drug is in a solubility-improved form and in the form of particles at least partially coated with the precipitation-inhibiting polymer. Exemplified low-solubility drugs are ziprasidone and sildenafil. Exemplified precipitation-inhibiting polymer is HPMCAS. | 06-04-2009 |
| 20090142405 | Nanoparticles for protein drug delivery - The invention discloses the nanoparticles composed of chitosan, poly-glutamic acid, and at least one protein drug or bioactive agent characterized with a positive surface charge and their enhanced permeability for paracellular protein drug and bioactive agent delivery. | 06-04-2009 |
| 20090169634 | DNA vaccine comprising IL-6-encoding DNA construct and applications thereof - The present invention provides a DNA vaccine, which comprises a DNA construct comprising an expression vector which is expressible in a eukaryotic cell, and a nucleotide fragment which comprises an IL-6-encoding sequence and an HPV E7-encoding sequence. In addition, the present invention also provides a pharmaceutical composition and a method of generating said DNA vaccine. | 07-02-2009 |
| 20100021550 | RADIOPAQUE BIODEGRADABLE VASCULAR EMBOLIC MICROSPHERES - A radiopaque biodegradable vascular embolic microsphere comprises of a biodegradable material and a radiopaque material which can be both delivered to the vascular system, in which, the biodegradable material incorporates the radiopaque material to form granule structure. The embolic microsphere, readily visible under X-ray, can be delivered or drift with blood flow to a peripheral vessel or site, and can be manufactured using a simple process. A radiopaque biodegradable vascular embolic microsphere incorporating therapeutic agent(s) comprises of a biodegradable material, a radiopaque material, and therapeutic agent(s), which can be all delivered to the vascular system, in which, the biodegradable material incorporates the radiopaque material and the therapeutic agent to form granule structure. This embolic microsphere can be delivered to the targeted site under X-ray guidance, and then embolize the site, and release the therapeutic agent directly at the targeted site while degrading in vivo. | 01-28-2010 |
| 20100098770 | SIROLIMUS PHARMACEUTICAL FORMULATIONS - Pharmaceutical formulations comprising sirolimus or its derivatives, processes for preparing formulations comprising sirolimus, and their methods of use, treatment, and administration. | 04-22-2010 |
| 20100112073 | Water-Soluble Nanoparticles Containing Water-Insoluble Compounds - Nanoparticles with entrapped, nonpolar compounds are disclosed, and a method for their synthesis. The nanoparticles are readily dissolved or dispersed in water. For example, the entrapped nonpolar compounds may include pharmaceutically-active compounds, or natural colorants. The nanoparticles have a nonpolar compound core, an intermediate surfactant layer, and an outer crosslinked polymeric protective layer. In a prototype example, alginic acid nanoparticles were prepared with beta-carotene entrapped in the core, with lecithin as the intermediate surfactant layer. In an alternative embodiment, a layer-by-layer assembly technique may be used to entrap the colorant within nanoparticles. | 05-06-2010 |
| 20100159017 | COMPOSITION OF BIOCOMPATIBLE MICROPARTICLES OF ALGINIC ACID FOR THE CONTROLLED RELEASE OF ACTIVE INGREDIENTS BY INTRAVENOUS ADMINISTRATION - The invention relates to a biocompatible composition which comprises microparticles of alginic acid or its salts and an active ingredient. More particularly, the invention relates to microparticles for the encapsulation of an active ingredient to be administered intravenously to a patient who needs it. These microparticles are of a combination of size sufficient to increase the half-life or survival of the active ingredient in blood, with a low uptake in the liver and a fast cell clearance when administered intravenously. | 06-24-2010 |
| 20100178352 | UNIFORMLY ABRASIVE CONFECTIONERY PRODUCT AND PROCESS THEREFOR - The present invention relates to the field of confectionery products. More particularly, the invention relates to an abrasive confectionery product and a process for producing the same. The product comprises abrasive inclusions which are uniformly dispersed throughout a base material. | 07-15-2010 |
| 20100203148 | Encapsulation and Controlled Release of Small Molecules for Intracellular Delivery Using Thermally Responsive Nanocapsules - In accordance with certain embodiments of the present disclosure, a method for intracellular delivery of small molecules is provided. The method includes encapsulation of small molecules in a thermally responsive nanocapsule by decreasing the temperature of the nanocapsule to increase the permeability of the nanocapsule and allowing the small molecules to be suck into or diffuse into the nanocapsule. The nanocapsule is delivered into a cell by increasing the temperature of the nanocapsule. The small molecules are released from the nanocapsule into the cell in a controllable manner by cooling and heating treatments. | 08-12-2010 |
| 20100209520 | ORAL PHARMACEUTICAL PREPARATION FOR COLON-SPECIFIC DELIVERY - The present invention relates to an oral pharmaceutical preparation having an excellent capability of delivering a drug to colon, more specifically an oral pharmaceutical preparation for delivering a drug to colon and comprising a core comprising at least a pharmaceutically acceptable vehicle, an inner layer covering said core and comprising said drug, an intermediate layer covering said inner layer and comprising a cationic polymer soluble or swellable at a pH of not more than 6.6, and an outer layer covering said intermediate layer and comprising an anionic polymer soluble at a pH of not less than 7.0. | 08-19-2010 |
| 20100215757 | ENVELOPE MEMBRANE FOR DISCHARGING AN ENCLOSED AGENT, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF - The invention relates to an enveloping membrane for discharging an enclosed agent in an aqueous medium. The aqueous solution of an oxidizing chlorine-oxygen compound is enclosed is said enveloping membrane which is insoluble in a neutral aqueous medium. In an advantageous embodiment, the enveloping membrane represents a capsule structure, particularly according to the core/shell principle. The core has a spongy, moist structure and contains the aqueous solution of an oxidizing chlorine-oxygen compound while the shell is water-insoluble and is provided with pores to discharge the chlorine-oxygen compound over an extended period of time, particularly in an aqueous medium. The enveloping membrane is suitable foremost for disinfecting and purifying/cleaning liquids and substrate surfaces, especially in the form of fabrics, filter materials, membranes, gaps, joints, and/or filling elements, for disinfecting water, particularly drinking water and bath water, and filter materials, where the inventive enveloping membrane discharges the agent into the medium or onto the substrate that is to be treated for an extended period of time, especially in a continuous and metered form. | 08-26-2010 |
| 20100215758 | EFFERVESCENT NUTRITIONAL AND/OR DIETARY SUPPLEMENT COMPOSITION - An effervescent composition is provided comprising a dry, free-flowing powder comprising (a) microcapsules comprising a hollow, solid, water soluble outer shell comprising a starch, a sugar or mixtures thereof and an inner core comprising a liquid, water immiscible oil comprising at least one polyunsaturated fatty acid, at least one derivative of a polyunsaturated fatty acid or mixtures thereof, and (b) an effervescing agent. | 08-26-2010 |
| 20100221351 | Controlled Drug Delivery Using a Thermally Responsive Nanocapsule to Augment Cryoablation - In accordance with certain embodiments of the present disclosure, A method for intracellular delivery of cytotoxin in combination with cyoablation is provided. The method includes encapsulation of one or more cytotoxins in a thermally responsive nanocapsule by decreasing the temperature of the nanocapsule to increase the permeability of the nanocapsule whereby the one or more cytotoxins are sucked into or diffuse into the nanocapsule. The temperature of the nanocapsule is increased and the nanocapsule is delivered into a cell. Cryoablation is performed in proximity to the cell resulting in the release of the one or more cytotoxins from the nanocapsule into the cell. | 09-02-2010 |
| 20100226995 | MICROENCAPSULATED BIOACTIVE AGENTS FOR ORAL DELIVERY AND METHODS OF USE THEREOF - The presently claimed and disclosed inventive concept(s) contemplates a novel polymeric oral dosage form (transmucosal delivery vehicle) for delivery of pharmaceutical and nutriceutical bioactive agents to the mucosa and bloodstream of the intestine. The oral dosage form of the presently claimed and disclosed inventive concept(s) comprises a polymeric coating which encapsulates the bioactive agent and inhibits degradation and dissolution of the bioactive agent within the stomach and within the lumen of the intestine until after passing through the mucosal wall of the small and/or large intestine. The enzymatic degradation of the polymeric delivery vehicle containing the bioactive agent is substantially inhibited until after absorption of the polymeric delivery vehicle into blood vessels of the intestinal mucosa. It is a particular object of the presently claimed and disclosed inventive concept(s) to provide a new and improved method for enterically or intestinally encapsulating pharmaceutical and nutriceutical bioactive agent or agents for oral administration of the encapsulated bioactive agent or agents. | 09-09-2010 |
| 20100266706 | ORAL PARTICULATE ANTITUMOR PREPARATION - An oral particulate antitumor preparation, which allows safe intake of antitumor agents, handling of which could be in many cases dangerous due to their high pharmacological activity, and has a stability equivalent to that of capsules or tablets, is provided. | 10-21-2010 |
| 20100272818 | COMPOSITIONS AND METHODS COMPRISING TERPENES OR TERPENE MIXTURES SELECTED FROM THYMOL, EUGENOL, GERANIOL, CITRAL, AND L-CARVONE - The present invention relates to compositions comprising terpenes which are particularly suitable for treating plant infections, to methods of making such compositions, and to methods of using them. The present invention also relates to compositions comprising terpenes and hollow glucan particles or cell wall particles and methods for preparing such compositions; such compositions increase terpene stability and activity and provide a suitable carrier for the terpenes. The invention also relates to methods of using such compositions in the medical, veterinary and agricultural fields. In particular, the terpenes disclosed are thymol, eugenol, geraniol, citral and L-carvone. | 10-28-2010 |
| 20100330188 | CARRIER PARTICLES FOR USE IN DRY POWDER INHALERS - A powder for use in a dry powder inhaler includes active particles and carrier particles for carrying the active particles. The powder further includes additive material on the surfaces of the carrier particles to promote the release of the active particles from the carrier particles on actuation of the inhaler. The powder is such that the active particles are not liable to be released from the carrier particles before actuation of the inhaler. The inclusion of additive material in the powder has been found to give an increased respirable fraction of the active material. | 12-30-2010 |
| 20110038940 | PULVERULENT COMPOSITION AND A PROCESS FOR PREPARING THE SAME - A pulverulent composition includes less than 96% in weight, preferably from 10 to 80%, and more preferably from 20% to 70%, of at least a vitamin having a solubility lower than 20 g/L and preferably 1 g/L and more preferably lower than 500 mg/L in aqueous media, the pulverulent composition being stable on storage and having instantaneous dispersion and solubility properties in aqueous solutions. | 02-17-2011 |
| 20110052711 | CONTROLLED RELEASE MULTIDRUG FORMULATIONS FOR SPINAL CORD INJURY - A controlled release multidrug formulation for improving locomotor recovery after spinal cord injury comprising: (a) a first composition comprising a first bioactive agent, encapsulated within a first polymeric particle; (b) a second composition comprising a second bioactive agent, encapsulated within a second polymeric particle, wherein the second polymeric particle is encapsulated within the first polymeric particle; and (c) a third composition comprising a third bioactive agent, encapsulated within either the first or the second polymeric particle, wherein the second composition is released subsequently to the release of the first composition, and wherein the first bioactive agent is a neurotrophic factor, the second bioactive agent is a collagen synthesis inhibitor, and the third bioactive agent is selected from the group consisting of cyclic AMP (cAMP), an adenylate cyclase activator and a Rho inhibitor. | 03-03-2011 |
| 20110052712 | Sprayable Polymers As Adhesion Barriers - A formulation for generating an adhesion barrier that includes a plurality of particles or a dry powder that is made of a polymer combination of at least one biodegradable polymer and at least one water soluble polymer is disclosed. Methods of making and delivering the formulation are further disclosed. The formulation of particles is deposited on a surface of internal body tissue and the deposited formulation absorbs moisture from the tissue and forms a film over the surface. The film acts as an adhesion barrier by reducing or preventing adhesion of the surface to other body tissue. | 03-03-2011 |
| 20110052713 | REPAIRING DAMAGED NERVOUS SYSTEM TISSUE WITH NANOPARTICLES - The present application relates to reduction of acrolein-mediated cell death following neural insult. According to at least one embodiment, chitosan is utilized as a membrane fusogen to restore cell function. According to at least one other embodiment, chitosan or silica is used to create a non-toxic polymer surfaced microcolloid (PSM). PSMs were found to preferentially target the damaged nerve tissues; to restore conduction of nerve impulses; to seal/restore nerve fiber membranes; and to reduce to baseline the efflux of a large intracellular enzyme. PSMs are further used as a drug delivery vehicle for acrolein scavengers including hydralazine. | 03-03-2011 |
| 20110076337 | EMULSIONS CONTAINING ARYLBORONIC ACIDS AND MEDICAL ARTICLES MADE THEREFROM - The invention provides emulsion compositions that include a hydrophobic compound and an arylboronic acid. An exemplary emulsion comprises a hydrophobic polymer and a halogenated arylboronic acid. Use of an arylboronic acid provides the emulsion with exceptional stability. The stability provides advantages for the formation of articles formed from the emulsion, including microparticles, as well as other implantable or injectable medical articles having polymeric matrices. | 03-31-2011 |
| 20110111041 | BACTERIALLY DERIVED INTACT MINICELLS THAT ENCOMPASS PLASMID FREE FUNCTIONAL NUCLEIC ACID FOR IN VIVO DELIVERY TO MAMMALIAN CELLS - Intact, bacterially-derived minicells can safely introduce therapeutically effective amounts of plasmid-free functional nucleic acid to target mammalian cells. To this end, functional nucleic acid can be packaged into intact minicells directly, without resort to expression constructs, the expression machinery of the host cell, harsh chemicals or electroporation. | 05-12-2011 |
| 20110111042 | SELF-MICROEMULSIFYING SYSTEMS INCORPORATED INTO LIQUID CORE MICROCAPSULES - The invention provides a microcapsule having a shell and a liquid core incorporating a self-microemulsifying system or a microemulsion, wherein the core comprises a lipophilic substance, at least one surfactant, an active agent, a gelling agent and optionally a cosolvent. Furthermore, a method for producing such microcapsules and pharmaceutical formulations comprising such microcapsules is provided. | 05-12-2011 |
| 20110171314 | NON-VIRAL COMPOSITIONS AND METHODS FOR TRANSFECTING GUT CELLS IN VIVO - The present invention provides chitosan-based nanoparticles that can protect nucleic acids and deliver the same into gut mucosal cells. Compositions and methods for the expression of therapeutic nucleic acids in cells of the gut mucosa are provided. Compositions and methods for delivering therapeutic proteins systemically from cells of the gut mucosa are also provided. | 07-14-2011 |
| 20110206772 | POLYSACCHARIDE COMPOSITION AND METHODS OF ISOLATION OF THE EMULSION STABILIZING CATIONIC POLYELECTROLYTIC POLYSACCHARIDE - The present invention relates to purification and use of a novel emulsion stabilizing polysaccharide. In particular, a polyelectrolyte exopolysaccharide with high molecular weight comprising a high molecular weight polymer with a tri-saccharide repeating unit is disclosed. In one aspect of the invention, methods are directed to isolating and purifying a high molecular weight exopolysaccharide (EPS) from a cell supernatant. In another aspect, methods are disclosed for isolating a lipopolysaccharide (LPS) and a high molecular weight | 08-25-2011 |
| 20110212181 | COMPOSITIONS AND METHODS FOR TREATING CHRONIC RESPIRATORY INFLAMMATION - Neutrophil elastase (NE) is a protease secreted by neutrophils during inflammation. Aberrant expression of NE such as in chronic respiratory inflammatory diseases, results in tissue destruction and decline in lung function. Compositions including an NE-targeting agent that targets the pathologic elements of respiratory inflammation are provided. Non-anticoagulant heparin derivatives or fragments are exemplary NE-targeting agents. The compositions preferably include a carrier, such as chitosan, to facilitate delivery of the active agent. Methods of manufacturing non-anticoagulant heparin are also provided. Methods of administering the disclosed compositions to treat respiratory diseases are also disclosed. In preferred methods, an effective amount of the pharmaceutical composition is administered to subject in need thereof to reduce, inhibit, or alleviate one or more symptoms of chronic respiratory inflammation. In the most preferred embodiment, the composition is administered as a dry powder, intranasally or by inhalation. | 09-01-2011 |
| 20110223256 | Method For Stabilizing Flavonoid Aqueous Dispersion - A method for suspending microparticulated water insoluble bioactive compound in a beverage by incorporating solubilized or dispersed microparticulated compound and at least one dispersion stabilizer into a beverage. A composition comprising solubilized or dispersed microparticulated water insoluble bioactive compound and a dispersion stabilizer agent. | 09-15-2011 |
| 20110229580 | COMPOSITIONS AND METHODS FOR NANO-IN-MICRO PARTICLES - Disclosed herein are compositions, methods and kits for a microsphere with one or more entrapped nanoparticles. The method of preparation comprises atomizing a suspension comprising a polysaccharide and one or more nanoparticles into a solution comprising a cross linking agent. | 09-22-2011 |
| 20110236495 | ANTI-CANCER NANOPARTICLE COMPOSITIONS AND METHODS OF USE - The present invention encompasses a composition capable of delivering and expressing a nucleic acid encoding UDP-Glucuronosyltransferases, p53 or a combination thereof into a cell, and methods for treating tumors. | 09-29-2011 |
| 20110244048 | MULTIFUNCTIONAL SELF-ASSEMBLING POLYMERIC NANOSYSTEMS - Libraries of nanoparticles comprising therapeutic agents and/or imaging agents are disclosed, as well as methods of making, customizing, and using such libraries of nanoparticles. | 10-06-2011 |
| 20110256230 | WATER INSOLUBLE POLYMER: INDIGESTIBLE WATER-SOLUBLE POLYSACCHARIDE FILM COATINGS FOR COLON TARGETING - A controlled release pharmaceutical dosage form for controlled release of an active ingredient, includes an active ingredient coated by a polymeric mixture of: at least a water insoluble polymer; and at least an indigestible water-soluble oligosaccharide. The use and method of making the same are also described. | 10-20-2011 |
| 20110262547 | PROCESS FOR PREPARING CARRIER PARTICLES FOR DRY POWDERS FOR INHALATION - Carrier particles in which at least 60% of the surface is coated with magnesium stearate are useful for preparing dry powder formulations for inhalation. | 10-27-2011 |
| 20110300222 | LUMINESCENT POROUS SILICON NANOPARTICLES, METHODS OF MAKING AND USING SAME - The disclosure relates to imaging agents and drug delivery systems. | 12-08-2011 |
| 20110300223 | IMMUNOGENIC COMPOSITION - An immunogenic composition includes as an effective ingredient an antigen-adjuvant microparticle complex containing an antigen encapsulated in an adjuvant microparticle composed of an amphiphilic polymer(s) whose hydrophobic segment is a poly(hydroxy acid), or a particle composed of the antigen-adjuvant microparticle complex associated together, can induce a high immune response against the antigen even with a small amount of the antigen and a small number of doses, so that the immunogenic composition is useful as a vaccine effective for therapy and prophylaxis of infectious diseases, cancer and the like. | 12-08-2011 |
| 20120003320 | Particles which are surface coated with hyaluronan or one of the derivatives thereof and the use of same as biological vectors for active substances - Particles comprising a core based on at least one biodegradable organosoluble polymer. At least a part of the surface of the particles is coated with at least one hyaluronan or a derivative thereof, the hyaluronan being a water-soluble, amphiphilic hyaluronan of which the carboxylic functions are in part transformed to form hydrophobic groups. | 01-05-2012 |
| 20120003321 | Crosslinked Dextran Composite Magnetic Microparticles and Preparation Process and Using Method Thereof - The present invention relates to crosslinked dextran magnetic composite microparticles and a preparation process and a using method thereof. The composite microparticles comprise magnetic nanoparticles and dextran with crosslinked structure, wherein the magnetic nanoparticles are dispersed in the dextran with crosslinked structure. The process for preparing the composite microparticles comprises: preparing a dextran solution; synthesizing dextran magnetic composite microparticles; and synthesizing the crosslinked dextran magnetic composite microparticles. The using method of composite microparticles comprises: preparing crosslinked dextran magnetic composite microparticles loaded with anti-cancer drug; and adding a sustained-releasing solution thereto. | 01-05-2012 |
| 20120015039 | SUSTAINED RELEASE OF NUTRIENTS IN VIVO - Nutritional compositions delivered in vivo in a time controlled manner sustainable over long periods of time, provide enhancing athletic performance, increased hand/eye coordination and concentration on the task at hand. | 01-19-2012 |
| 20120058192 | SUNSCREEN COMPOSITIONS - Sunscreen compositions containing a discontinuous oil phase dispersed in a continuous water phase, at least 10% by weight of an organic UV-filter, a water-insoluble, C | 03-08-2012 |
| 20120058193 | INJECTABLE SMART GEL AND METHOD FOR FABRICATING THE SAME - An injectable smart gel and a method for fabricating the same are disclosed. A basic structural stabilizer/polymeric electrolyte and a diluting solution are added to a modified chitosan to regulate the chitosan solution to have a pH value closing to that of the human body and form a flowable chitosan sol. The flowable chitosan sols formed thereby are respectively converted into inflowable chitosan gels via increasing the temperature thereof to the human body temperature, and via adding calcium ion or regulating the chitosan sol into an acidic solution. The injectable smart gel fabricated thereby is injectable and able to function as a carrier of magnetism-sensitive medicine-containing nanocapsules. The medicine can be released to the injectable smart gel with an external non-contact force, such as a magnetic field, an electric field or an ultrasonic wave, for long-acting and multi-stage medicine delivery. The present invention is very useful in biomedical engineering. | 03-08-2012 |
| 20120100220 | DRUG COMPOSITION FOR TREATING TUMOR WITH POLYMERIC MICELLE ENCAPSULATING ANTI-NEOPLASTIC - This present disclosure relates to pharmaceutical compositions for treating tumors using a polymeric micelle encapsulating an anti-tumor drug. The polymeric micelle comprises block copolymers comprising at least one hydrophilic block, at least one hydrophobic block, and at least one zwitterion. The present disclosure also relates to methods of enhancing the solubility of such drugs, methods of increasing the blood circulating time of such drugs, and methods of delivering such drugs to one or more solid tumors. | 04-26-2012 |
| 20120121717 | DRUG-LOADED POLYSACCHARIDE-COATED GOLDMAG PARTICLES (DPGPs) AND ITS SYNTHESIS METHOD - The invention relates to Polysaccharide-coated GoldMag particles (DPGPs) and the method of its synthesis, which characterized GoldMag particles as a core and natural or synthetic biodegradable polysaccharide such as dextran, cyclodextrin and derivatives as shell. DPGPs are synthesized by mixing Polysaccharide-coated GoldMag particles (DPGPs) with drug through physical bond. The preparation of the drug-loaded composite particles include: preparing the polysaccharide-coated GoldMag particles and then loading the drug on the polysaccharide-coated GoldMag particles. The drug-loading process is carried out through directly mixing the polysaccharide-coated GoldMag particles with the drug solution by the shaker. That means the polysaccharide-coated GoldMag particles load the drug through affinity adsorption. | 05-17-2012 |
| 20120128781 | FUNCTIONALIZATION OF NANOPARTICLES BY GLUCOSAMINE DERIVATIVES - The present invention relates to oligomeric or polymeric saccharide derivatives comprising glucosamine moieties, e.g. derivatives of oligomeric or polymeric glucosamines such as chitosan oligomers or polymers, in which one or more amine groups are substituted by anchoring groups that chemisorb to the surface of a nanoparticle or form an interdigitated bilayer with a surfactant layer surrounding the nanoparticle. The invention also relates to functionalized nanoparticles comprising such derivatives, a method for forming the functionalized particles and to uses thereof as molecular imaging agents, biosensing agents or drug delivery agents, or in the preparation of such agents. | 05-24-2012 |
| 20120148678 | SUSTAINED RELEASE OF POORLY WATER SOLUBLE ACTIVE COMPOUNDS - We have disclosed an implantable sustained release composition comprising, a biocompatible, biodegradable polymer, a cyclodextrin inclusion complex of a poorly water soluble pharmaceutical agent present, and a plasticizer, where the polymer is the minority phase of the formulation. Furthermore, The we disclose an implantable sustained release composition that provides a detectable plasma level of an otherwise poorly soluble drug for at least 28 days. | 06-14-2012 |
| 20120171295 | METHODS FOR CRYOPRESERVING AND ENCAPSULATING CELLS - Described herein are methods of cryopreserving cells that have been suspended in alginate as well as methods for encapsulating cryopreserved cells that have been suspended in alginate. Further provided herein are cellular compositions comprising cells that have been processed in accordance with the methods described herein. | 07-05-2012 |
| 20120189704 | NOVEL INJECTABLE CHITOSAN MIXTURES FORMING HYDROGELS - A chitosan composition which forms a hydrogel at near physiological pH and 37° C., comprising at least one type of chitosan having a degree of acetylation in the range of from about 30% to about 60%, and at least one type of chitosan having a degree of deacetylation of at least about 70% is disclosed. Further disclosed is a chitosan composition which forms a hydrogel at near physiological pH and 37° C., comprising at least one type of chitosan having a degree of deacetylation of at least about 70% and a molecular weight of from 10-4000 kDa, and at least one type of a chitosan having a molecular weight of from 200-20000 Da. Further disclosed are methods of preparation and uses of the chitosan compositions. | 07-26-2012 |
| 20120207842 | MULTIPARTICULATE L-MENTHOL FORMULATIONS AND RELATED METHODS - Enteric coated multiparticulate formulations that use L-menthol as an active ingredient are disclosed. In one embodiment, the multiparticulate formulation comprises a plurality of particulates having a reduced release under gastric conditions and an elevated release at neutral pH. The particulates comprise a core comprising L-menthol as an active ingredient. The L-menthol is supplied to the core as an at least 80% pure L-menthol material. An enteric coating is over the core. The enteric coating is effective to release at least about 80% of the L-menthol within about two hours of being placed in a substantially neutral pH environment. Other aspects of the invention include methods of making and methods of using the multiparticulate formulations. | 08-16-2012 |
| 20120263794 | TREATMENT OF EYE DISEASES USING ENCAPSULATED CELLS ENCODING AND SECRETING A NEUROPROTECTIVE FACTOR AND/OR AN ANTI-ANGIOGENIC FACTOR - The present application refers to cells, e.g. mesenchymal stem cells or mesenchymal stromal cells, or any further suitable cell, encoding and secreting a neuroprotective factor, an anti-angiogenic factor and/or any other protein or protein-like substance suitable for (intraocular) treatment of eye diseases. Such eye diseases include glaucoma and other optic nerve disorders, retinal diseases, particularly retinitis pigmentosa (RP), age-related macular degeneration (AMD) and diabetic retinopathy, etc. The cells used herein are encapsulated in a (spherical) microcapsule, preferably comprising a core and at least one surface layer, to prevent a response of the immune system of the patient to be treated. The present application also refers to the use of these (spherical) microcapsule(s) or such factors for (intraocular) treatment of eye diseases as defined herein (for the preparation of a (pharmaceutical) composition) for the treatment of such eye diseases. | 10-18-2012 |
| 20120282342 | METHOD FOR PREPARING POLYSACCHARIDE NANOCOMPOSITE PARTICLES AND USES OF THE SAME - A method for preparing polysaccharide nanocomposite particles is provided. The method comprises providing a first solution comprising an active component and a polysaccharide; adding a cross-linking agent to the first solution to provide a second solution; and allowing the second solution to conduct the reaction to form polysaccharide nanocomposite particles. The polysaccharide nanocomposite particles thus prepared show good coating ratio and enhanced applicability. Also provided is a method for inducing cancer cell apoptosis in a subject, comprising administrating to the subject an effective amount of the polysaccharide nanocomposite particles. | 11-08-2012 |
| 20120294946 | MODULATOR - There is provided a method for suppressing a pro-inflammatory immune response in a cell, comprising providing to a cell sialic acid or analogs thereof, wherein the sialic acid or analogs are presented by a substrate such that a pro-inflammatory immune response in a cell is suppressed or an anti-inflammatory immune response is increased in a cell. Further, there is provided a method of treatment of inflammatory disease in a subject in need thereof. There is also provided a drug delivery device and a biomaterial which can modulate the inflammatory response in a subject. | 11-22-2012 |
| 20120328704 | POWDER COMPOSITIONS FOR INHALATION - The present invention relates to newly identified genes that encode proteins that are involved in the synthesis of L-ascorbic acid (hereinafter also referred to as Vitamin C). The invention also features polynucleotides comprising the full-length polynucleotide sequences of the novel genes and fragments thereof, the novel polypeptides encoded by the polynucleotides and fragments thereof, as well as their functional equivalents. The present invention also relates to the use of said polynucleotides and polypeptides as biotechnological tools in the production of Vitamin C from microorganisms, whereby a modification of said polynucleotides and/or encoded polypeptides has a direct or indirect impact on yield, production, and/or efficiency of production of the fermentation product in said microorganism. Also included are methods/processes of using the polynucleotides and modified polynucleotide sequences to transform host microorganisms. The invention also relates to genetically engineered microorganisms and their use for the direct production of Vitamin C. | 12-27-2012 |
| 20130022682 | Ultra-Stable Oligonucleotide-Gold And-Silver Nanoparticle Conjugates And Method Of Their Preparation - A method for stabilizing conjugates between macromolecule and nanoparticle by forming a thin reinforcement layer over the surface of a nanoparticle after macromolecule chains have attached to the surface of the nanoparticle. The stabilized conjugates can be used in a wide range of applications such as in vitro diagnostics, in vivo imaging and therapeutics, which need to be conducted under various severe or harsh conditions. | 01-24-2013 |
| 20130071479 | Microspheres - The disclosure relates to substantially uniform, high density microspheres and methods of making the microspheres. The microspheres can be made to be small in size with a narrow range of particle size distribution and a high sphericity. In one aspect, the microspheres provided herein are provided in the form of spherical cores comprising maltodextrin or maltodextrin and starch and are prepared using a centrifugal tumbling-granulating-coating apparatus. In another aspect, the spherical cores can be powder-coated with one or more layers of small particles, such as starch particles. The microspheres provided herein can be used as cores for multi-particulate solid dosage delivery systems as well as other pharmaceutical, nutraceutical, food, personal care, and other applications. | 03-21-2013 |
| 20130071480 | Particles which are surface coated with hyaluronan or one of the derivatives thereof and the use of same as biological vectors for active substances - Particles having a core based on at least one biodegradable organosoluble polymer. At least a part of the surface of the particles is coated with at least one hyaluronan or a derivative thereof, the hyaluronan being a water-soluble, amphiphilic hyaluronan of which the carboxylic functions are in part transformed to form hydrophobic groups. | 03-21-2013 |
| 20130078309 | ORAL PARTICULATE ANTITUMOR PREPARATION - An oral particulate antitumor preparation, which allows safe intake of antitumor agents, handling of which could be in many cases dangerous due to their high pharmacological activity, and has a stability equivalent to that of capsules or tablets, is provided. An oral particulate antitumor preparation, in which a particulate composition containing an antitumor agent is coated with a saccharide other than a cellulose derivative. | 03-28-2013 |
| 20130089615 | Compositions of Jasmonate Compounds and Methods of Use - The disclosure describes nanocarried and/or microcarried jasmonate compounds and their pharmaceutical compositions, as well as use thereof for treating or preventing angiogenesis-related or NF-κB-related disorders. Also disclosed are methods of making the nanocarried and/or microcarried compounds and their compositions. | 04-11-2013 |
| 20130095186 | TEMPERATURE-SENSITIVE CARRIER FOR CARRYING A PHYSIOLOGICALLY ACTIVE SUBSTANCE AND PREPARATION METHOD THEREOF - The present invention relates to a temperature-sensitive carrier for carrying a physiologically active substance and a preparation method thereof. Specifically, the temperature-sensitive carrier according to the present invention comprises an amphiphilic biodegradable block copolymer containing polysaccharide or polysaccharide and succinic anhydride as a hydrophilic block and polylactide as a non-ionic block. A hydrophilic polymer-polylactide copolymer according to the present invention forms a stable complex with a physiologically active substance such as protein, polynucleotide and the like in vivo via ionic bonding and temperature-sensitive hydrophobic bonding. Therefore, a copolymer according to the present invention can facilitate in vivo delivery of a physiologically active substance and used as an in vivo drug delivery system. | 04-18-2013 |
| 20130095187 | COMPOSITION FOR NUCLEIC ACID DELIVERY USING METAL NANOPARTICLES AND PREPARING METHOD THEREOF - The present invention relates to a composition for nucleic acid delivery and a method for preparing the same, more particularly to a composition for nucleic acid delivery having excellent stability in the body environment and excellent intracellular delivery efficiency of nucleic acid, and enabling target directed delivery of nucleic acid, and a method for preparing the same. | 04-18-2013 |
| 20130115297 | STABLE, DURABLE GRANULES WITH ACTIVE AGENTS - A stable, durable granule for feed compositions has a core, at least one active agent; and at least one coating. The active agent of the granule retains at least 50% activity, at least 60% activity, at least 70% activity, at least 80% activity after conditions selected from one or more of a) a feed pelleting process, b) a steam-heated feed pretreatment process, c) storage, d) storage as an ingredient in an unpelleted mixture, and e) storage as an ingredient in a feed base mix or a feed premix comprising at least one compound selected from trace minerals, organic acids, reducing sugars, vitamins, choline chloride, and compounds which result in an acidic or a basic feed base mix or feed premix. | 05-09-2013 |
| 20130129829 | Encapsulation and Controlled Release of Small Molecules for Intracellular Delivery Using Thermally Responsive Nanocapsules - In accordance with certain embodiments of the present disclosure, a method for intracellular delivery of small molecules is provided. The method includes encapsulation of small molecules in a thermally responsive nanocapsule by decreasing the temperature of the nanocapsule to increase the permeability of the nanocapsule and allowing the small molecules to be suck into or diffuse into the nanocapsule. The nanocapsule is delivered into a cell by increasing the temperature of the nanocapsule. The small molecules are released from the nanocapsule into the cell in a controllable manner by cooling and heating treatments. | 05-23-2013 |
| 20130149385 | NANOFORMULATION OF VITAMIN D DERIVATIVES AND/OR VITAMIN D METABOLITES - A nanoformulation that includes loaded nanoparticles. Each nanoparticle includes a modified chitosan polymer encapsulating at least one vitamin D derivative, at least one vitamin D metabolite, or combinations thereof. The modified chitosan polymer includes chitosan covalently linked to at least one entity selected from the group consisting of fatty acids (omega-3-fattay acids), amino acids, deoxycholic acid, alginate, arginine-alginate, hyaluronic acid, collagen, collagen-hydroxyapatite, poly(lactic-co-glycolic acid) (PLGA), and combinations thereof. A structure includes a medium and the nanoformulation, wherein the nanoparticles are dispersed in the medium. A method of using the nanoformulation to treat a disorder and improve efficacy of current therapies where resistance develop in a patient includes administering to the patient a therapeutically effective amount of the nanoformulation for treating the disorder. A nano-cosmetic formulation, comprising a cosmetic includes the nanoformulation, wherein the modified chitosan polymer encapsulates the at least one vitamin D derivative, and wherein the at least one vitamin D derivative encompasses 0.1 to 20.0 wt % of the nano-cosmetic formulation's total weight. | 06-13-2013 |
| 20130156858 | Formulations Preserving Bioactivity and Methods of Their Preparation - A pharmaceutical composition comprising an alginate hydrogel core where a bioactive agent is entrapped. The water content of the hydrogel is at least 10% of equilibrium water content. The beads have an enteric coating and are intended for oral administration. The bioactive agent is bioactive proteins, antibodies or viable cells and it is intended to exert its activity in the duodenum and the upper intestines. | 06-20-2013 |
| 20130156859 | IMMUNOGENIC COMPOSITION - An immunogenic composition includes as effective ingredients: an immunogenic micro-particle composed of an antigen-adjuvant microparticle complex wherein an antigen(s) is/are encapsulated in an adjuvant microparticle composed of an amphiphilic polymer(s) whose hydro-phobic segment(s) is/are poly(hydroxy acid); and a surfactant encapsulated in the immunogenic microparticle. | 06-20-2013 |
| 20130189367 | NANOVECTORS FOR TARGETED GENE SILENCING AND CYTOTOXIC EFFECT IN CANCER CELLS - Nanoparticle having a coating comprising a polyethylenimine and a chitosan-polyethylene oxide oligomer copolymer, and methods for making and using the nanoparticle. The nanoparticle can have a core that includes a material that imparts magnetic resonance imaging activity to the particle and, optionally, include one or more of an associated therapeutic agent, targeting agent, and fluorescent agent. | 07-25-2013 |
| 20130189368 | NANOPARTICULATE COMPOSITION CONTAINING ANTIBIOTICS FOR INTRAMAMMARY ADMINISTRATION IN ANIMALS - The present invention relates to the development of two types of polymer nanocapsules to encapsulate cloxacillin benzathine, an antimicrobial drug. More specifically, this invention relates to a new form of treatment for mastitis in dairy cattle. Two nanocapsule formulations have been developed and can be used to encapsulate various drugs, besides cloxacillin benzathine, providing a new therapy for mastitis in cows, avoiding the inconvenience of the use of high doses of drugs used in conventional formulations, thus contributing to an improvement in milk quality. | 07-25-2013 |
| 20130224304 | EFFERVESCENT NUTRITIONAL AND/OR DIETARY SUPPLEMENT COMPOSITION - An effervescent composition is provided comprising a dry, free-flowing powder comprising (a) microcapsules comprising a hollow, solid, water soluble outer shell comprising a starch, a sugar or mixtures thereof and an inner core comprising a liquid, water immiscible oil comprising at least one polyunsaturated fatty acid, at least one derivative of a polyunsaturated fatty acid or mixtures thereof, and (b) an effervescing agent. | 08-29-2013 |
| 20130230595 | Methods of Using Multilayer Magnetic Micelle Compositions - Provided herein is a method of transfecting a brain cell of a subject with a polynucleotide comprising systemically administering to the subject a composition comprising a micelle having a hydrophobic superparamagnetic iron oxide nanoparticle (SPION) core, a first coating comprising a cationic polymer, and a second coating comprising the polynucleotide, wherein the subject has a mild traumatic brain injury. | 09-05-2013 |
| 20130243867 | MICELLE COMPOSITIONS AND METHODS FOR THEIR USE - Provided herein is a micelle composition comprising a polyethylene glycol (PEG), a DC-cholesterol, and a dioleoylphosphatidyl-ethanolamine (DOPE) and either or both a pharmaceutical compound core and a polynucleotide coating. Also provided herein is a method of administering one or more compounds to a cell comprising administering to the cell a micelle composition comprising 1) PEG-PE, a DC-cholesterol, and DOPE, and 2) the one or more compounds, wherein the compounds are selected from the group consisting of a polynucleotide and a pharmaceutical composition. Further provided are methods for detecting the micelle composition. | 09-19-2013 |
| 20130243868 | NOVEL FORMULATIONS - Nanoparticles comprising T3 and their use in treating, e.g., cardiac conditions, for example cardiac arrest, are provided. Such nanoparticles provide improved delivery of T3 and allow for acute treatment and optionally for sustained release of T3 in a patient. | 09-19-2013 |
| 20130273170 | PUUMALA VIRUS FULL-LENGTH M SEGMENT-BASED DNA VACCINES - The invention contemplates a new synthetic, codon-optimized | 10-17-2013 |
| 20130295187 | NOVEL FORMULATIONS OF FACTOR VIIa INHIBITORS AND UTILITY - A method for treating a subject, such as a human patient, having a vascular disorder. The treatment method administers a therapeutic effective amount of a nanoparticle or a chemical structure to the subject to treat the disorders. The nanoparticle includes a poly L-arginine polymer and a Factor VIIa inhibitor conjugated to, or encapsulated in, the poly L-arginine polymer. The chemical structure includes a Factor VIIa inhibitor that includes at least one nitric oxide (NO) donor. The disorder may be sickle cell disease; stimulated or pathological angiogenesis associated disorders, cancer, ocular angiogenesis-mediated disorders such as diabetic retinopathy and macular degeneration, coagulation and/or platelet activation-associated disorders, pulmonary hypertension, or combinations thereof. | 11-07-2013 |
| 20130316007 | Microcapsule Preparation of Alginate-Chitosan Acyl Derviatives, Preparation and Application Thereof - The present invention relates to a microcapsule preparation product of alginate-chitosan acyl derivatives, which is produced by mixing microcapsules of alginate-chitosan acyl derivatives with an aqueous solution, wherein the biomicrocapsule structureconsists of two parts, a microcapsule membrane and an inner core; the microcapsule membrane is a polyelectrolyte composite hydrogel membrane formed by chitosan, alginates and chitosan acyl derivatives, and the inner core is an alginate liquid or a hydrogel environment containing cells. | 11-28-2013 |
| 20130337070 | Coated Nanoparticle Therapy for Skin Cancer - Disclosed herein are compositions useful as therapy and prevention of skin neoplasms, namely melanoma. Also disclosed herein are methods of using polymer-coated cerium nanoparticles as therapy against skin cancer. Further, disclosed are combination therapies involving polymer-coated cerium nanoparticles with other anti-neoplastic agents. | 12-19-2013 |
| 20140017326 | NOVEL POLYSACCHARIDE DERIVATIVES AND DOSAGE FORMS - Polysaccharide derivatives having a median Equivalent Projected Circle Diameter (EQPC) of less than 140 micrometers and a particle size and shape distribution meeting condition A or B or both are useful for preparing dosage forms, particularly for preparing compressed sustained-release dosage forms: A. non-compacted polysaccharide derivative particles have a flowability of at least 45 g/sec through a vertically inverted cone having a vertex angle of about 40 and an outlet diameter of about 50 mm, or B. i) no more than 40 volume percent of the polysaccharide derivative particles are fine particles having a particle length LEFI of less than 40 micrometers and ii) no more than 40 volume percent of the polysaccharide derivative particles are fibrous particles, and the sum of the fine particles and the fibrous particles does not exceed 50 volume percent. | 01-16-2014 |
| 20140037742 | ALGINATE MICROPARTICLES AND METHODS OF USING THE SAME - By combining the anti-bacterial effects of silver sulfadiazine and silver nanoparticles with the absorption and slow-release capabilities of alginate, a product was created that can be used to heal and protect deep wounds. These microparticles can have a greater surface area to volume ratio. This, in turn, can permit the particles to have a larger area of exposure to bacterial colonies, thereby increasing antimicrobial activity. Additionally, engineered microparticles also may benefit from the ability to conform to the shape of the wound. | 02-06-2014 |
| 20140037743 | MICROENCAPSULATED BIOACTIVE AGENTS FOR ORAL DELIVERY AND METHODS OF USE THEREOF - The presently claimed and disclosed inventive concept(s) contemplates a novel polymeric oral dosage form (transmucosal delivery vehicle) for delivery of pharmaceutical and nutriceutical bioactive agents to the mucosa and bloodstream of the intestine. The oral dosage form of the presently claimed and disclosed inventive concept(s) comprises a polymeric coating which encapsulates the bioactive agent and inhibits degradation and dissolution of the bioactive agent within the stomach and within the lumen of the intestine until after passing through the mucosal wall of the small and/or large intestine. The enzymatic degradation of the polymeric delivery vehicle containing the bioactive agent is substantially inhibited until after absorption of the polymeric delivery vehicle into blood vessels of the intestinal mucosa. It is a particular object of the presently claimed and disclosed inventive concept(s) to provide a new and improved method for enterically or intestinally encapsulating pharmaceutical and nutriceutical bioactive agent or agents for oral administration of the encapsulated bioactive agent or agents. | 02-06-2014 |
| 20140037744 | MICROCAPSULES CONTAINING AN OXIDIZABLE ACTIVE, AND A PROCESS FOR PREPARING THE SAME - Disclosed is a microcapsule including a core having an oxidizable active (OA), the outer part of said core being in a solid form, and a water insoluble coating obtained from an encapsulating agent (EA), with the coating surrounding said core. In particular, there is disclosed a microcapsule wherein the EA is water soluble or organic solvent, in particular ethanol, soluble, or a microcapsule wherein said EA is an agent, the water solubility of which is pH-dependent. In particular, the core does not consist in or comprise a metal oxide, and the coating does not comprise a disintegrant, in particular sodium starch glycolate. Also disclosed is a process for preparing the microcapsules. | 02-06-2014 |
| 20140079789 | Bioglass with Glycosaminoglycans - One or more particles of bioactive glass coated with a glycosaminoglycan, wherein the glycosaminoglycan is bound to the bioactive glass and methods of treatment using such particles. | 03-20-2014 |
| 20140147508 | Nano-Carrier, Complex of Anticancer Drug and Nano-Carrier, Pharmaceutical Composition Thereof, Method for Manufacturing the Complex, and Method for Treating Cancer by Using the Pharmaceutical Composition - The present invention relates to a nano-carrier for an anticancer drug, which comprises: a metal nanoparticle; and a polynucleotide for connecting with an anticancer drug having a pyrimidine group or a purine group, wherein the polynucleotide is connected to a surface of the metal nanoparticle, and the anticancer drug is bound to the polynucleotide through the pyrimidine group or the purine group. In addition, the present invention also provides a complex of an anticancer drug and a nano-carrier, a pharmaceutical composition thereof, a method for manufacturing the complex, and a method for treating a cancer by using the pharmaceutical composition. | 05-29-2014 |
| 20140212502 | NANO- AND MICRO-BUBBLES WITH ULTRASOUND-TRIGGERED RELEASE AND IMAGING FUNCTIONALITIES - The present invention relates to a novel nano-/micro-bubble drug vehicle with functions of carrying hydrophobic drugs, ultrasound-triggered release and magnetic resonance or optical imaging, made of amphiphilic chitosan polymer material, and lipophlic superparamagnetic iron oxide (SPIO) or luminous nanoparticles. By using magnetic resonance or optical imaging to track the location of the drug vehicle, a user can trigger the release of drug by ultrasonication when the drug vehicle arrives at target site and accumulates to a desirable concentration. The nano-/micro-bubble drug delivery system provides improved accuracy of drug releasing, including position and timing, and thus reduces side effects of the drug. In addition, the synergistic effect of the amphiphilic chitosan molecules and sonication may improve the transmembrane delivery of hydrophobic agent into target cell, and enhance the cytotoxicity of anti-cancer drugs. | 07-31-2014 |
| 20140220148 | DIAMINOOXIDASE-CONTAINING PHARMACEUTICAL COMPOSITIONS - The present invention relates to pharmaceutical compositions, food supplement compositions and cosmetic compositions comprising diaminooxidase, and to the use thereof. | 08-07-2014 |
| 20140242177 | EPINEPHRINE NANOPARTICLES, METHODS OF FABRICATION THEREOF, AND METHODS FOR USE THEREOF FOR TREATMENT OF CONDITIONS RESPONSIVE TO EPINEPHRINE - The invention provides compositions including epinephrine nanoparticles and methods for therapeutic use of the compositions in the treatment of conditions responsive to epinephrine such as a cardiac event or an allergic reaction, particularly anaphylaxis. The epinephrine nanoparticles can be incorporated into orally-disintegrating and fast-disintegrating tablet pharmaceutical formulations and can significantly increase the sublingual bioavailability of epinephrine, and thereby reduce the epinephrine dose required. Additionally, the invention provides methods for fabrication of stabilized epinephrine nanoparticles for use in the described compositions. | 08-28-2014 |
| 20140248366 | ANIMAL FEED COMPOSITION - The present invention relates to a feed composition for an animal comprising tea tree oil, wherein the tea tree oil is present in an amount sufficient to reduce bacterial infection in the animal upon ingestion of the feed composition, and to methods for preparing such a composition. | 09-04-2014 |
| 20140308359 | EASILY DOSABLE SOLID PREPARATION - It has been desired to develop a coating composition, which is used for an orally-administered preparation having an improved administering property, and/or an easily administrable preparation that does not affect dissolution property. The present invention provides a coating composition comprising: a first thickener selected from the group consisting of a carboxyvinyl polymer and sodium alginate; a polyvalent metal compound; at least one type of a second thickener selected from the group consisting of xanthan gum, guar gum and sodium alginate, with the proviso that when the first thickener is sodium alginate the second thickener is not sodium alginate; and sucralose. | 10-16-2014 |
| 20140322341 | NOVEL HEMOSTATIC PATCH AND USES THEREOF - Disclosed herein is a novel hemostatic patch that may be used to control and/or arrest bleeding in patients. The patch offers an effective but also minimally invasive way to control and/or arrest bleeding in a patient. The patch comprises a mucoadhesive and a compound that causes vasoconstriction. In a preferred aspect, the patch comprises chitosan and Neuropeptide Y. Also disclosed are methods of using the novel hemostatic patch. | 10-30-2014 |
| 20140322342 | CO-ENCAPSULATION OF LIVE CELLS WITH OXYGEN-GENERATING PARTICLES - Microcapsules are described that comprise (a) a liquid aqueous or hydrogel core; (b) a semipermeable membrane surrounding said core; (c) live animal cells (e.g., pancreatic cells) in the core; and (d) oxygen-generating particles in said core, said oxygen-generating particles included in said microcapsules in an amount sufficient to lengthen the duration of viability of said animal cells in said microcapsules. Compositions comprising such microcapsules and uses thereof, such as in treating diabetes, are also described. | 10-30-2014 |
| 20140328933 | NOVEL FORMULATIONS AND METHODS - Nanoparticles comprising VIP and their use in treating, e.g. pulmonary hypertension. Such nanoparticles provide improved delivery of VIP and allow for acute treatment and optionally for sustained release of VIP in a patient. | 11-06-2014 |
| 20140363515 | BEADLETS COMPRISING HOP ACID SALTS IN A STARCH MATRIX - The present invention relates to a process for production of beadlets comprising hop acids salts in a matrix comprising at least one starch and/or starch derivative, to such beadlets and to the use of such specific beadlets. | 12-11-2014 |
| 20140370111 | PROTEIN DELIVERY FROM STEM CELL MICROCARRIERS - Disclosed are methods and compositions of microbead carriers for delivery of cells and other biologically active substances to diseased or damaged tissue in a subject in need thereof. | 12-18-2014 |
| 20150024057 | NON-DIGESTIBLE SUGAR-COATED PRODUCTS AND PROCESS - A method and composition are provided for coating a component to achieve colon-targeted delivery. A component is coated with a fructose-based non-digestible carbohydrate such as a inulin, fructo-oligosaccharide or neosugar. The coated component is orally administered to a monogastric animal. The non-digestible coating causes the composition to pass through the stomach and small intestine without being degraded, and delivers the component to the colon where the coating is digested by microbial fermentation and the component is released. | 01-22-2015 |
| 20150030683 | FORMULATIONS AND METHODS FOR THE TREATMENT OR PROPHYLAXIS OF PRE-MCI AND/OR PRE-ALZHEIMER'S CONDITIONS - In certain embodiments the methods of preventing or delaying the onset of a pre-Alzheimer's condition and/or cognitive dysfunction, and/or ameliorating one or more symptoms of a pre-Alzheimer's cognitive dysfunction, and/or preventing or delaying the progression of a pre-Alzheimer's condition or cognitive dysfunction to Alzheimer's disease, and/or of promoting the processing of amyloid precursor protein (APP) by the non-amyloidogenic pathway are provided. In certain embodiments the methods involve administering, or causing to be administered, to a subject in need thereof certain formulations comprising or more active agent(s) selected from the group consisting of tropisetron disulfiram, honokiol, nimetazepam, and/or derivatives or analogs thereof. | 01-29-2015 |
| 20150030684 | IRRIGATION RESISTANT COMPOSITIONS FOR REGENERATION OF HARD TISSUES AND METHODS AND KITS OF USING THE SAME - An irrigation resistant bone repair composition including a biocompatible or bioactive bone repair material and a mixture of non-random poly(oxyalkylene) block copolymers is described. Also, methods for treating a bone having a bone gap or a bone defect with the composition including a biocompatible or bioactive bone repair material and a mixture of non-random poly(oxyalkylene) block copolymers are also provided. Also, kits including the irrigation resistant bone repair composition including a biocompatible or bioactive bone repair material and a mixture of non-random poly(oxyalkylene) block copolymers are described. | 01-29-2015 |
| 20150125538 | COMPOSITIONS AND METHODS FOR OXALATE REDUCTION - The present invention comprises methods and compositions for the reduction of oxalate in humans. For example, the invention provides methods and compositions for the delivery of one or more oxalate-reducing enzymes embedded in particle compositions. The compositions of the present invention are suitable in methods of treatment or prevention of oxalate-related conditions including, but not limited to, hyperoxaluria, absorptive hyperoxaluria, enteric hyperoxaluria, primary hyperoxaluria, idiopathic calcium oxalate kidney stone disease (urolithiasis), vulvodynia, oxalosis associated with end-stage renal disease, cardiac conductance disorders, inflammatory bowel disease, Crohn's disease, ulcerative colitis, and patients who have undergone gastrointestinal surgery and bariatric surgery (surgery for obesity), and/or who have undergone antibiotic treatment. | 05-07-2015 |
| 20150140106 | OCULAR NANOFORMULATION AND METHOD OF USE IN ANGIOGENESIS-MEDIATED DISORDERS - An ophthalmic formulation that includes nanoparticles. Each nanoparticle includes a shell which encapsulates sulfated non-anticoagulant heparin (SNACH), with or without hydrophobic anti-angiogenesis Tyrosine Kinase inhibitors. The SNACH is ionically or covalently bonded to the shell. The shell includes a polymer selected from the group consisting of poly (lactic-co-glycolic acid) (PLGA), chitosan, chitosan-alginate, and NIPAAM-APMAH-AA, wherein NIPAAM is N-isopropyl acrylamide, APMAH is N-3-aminopropylmethacrylamide hydrochloride, and AA is acrylic acid. A method for treating an eye disease of a subject includes: administering to an eye of the subject a therapeutically effective amount of the ophthalmic formulation for treating the eye disease. The eye disease involves an ocular angiogenesis-mediated disorder. | 05-21-2015 |
| 20150289550 | METHOD FOR PRODUCING SWEETENER COMPOSITIONS AND SWEETENER COMPOSITIONS - Provided herein are compositions with enhanced sweetness or reduced caloric content per weight when compared to the sweetener carbohydrate or sweetener polyol component thereof, and methods for the preparation thereof. | 10-15-2015 |
| 20150290141 | CLINICAL GRADE SODIUM ALGINATE FOR MICROENCAPSULATION OF MYOFIBROBLASTS ISOLATED FROM WHARTON JELLY FOR PREVENTION AND TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES - A method for microencapsulation includes isolating myofibroblasts from Wharton's jelly of a human umbilical cord. The myofibroblasts are microencapsulated using ultra-purified sodium alginate, wherein the myofibroblasts encapsulated in the sodium alginate form a three-dimensional spherical structure. | 10-15-2015 |
| 20150306134 | APPLICATION OF MALTOTRIOSE-COATED 4TH GENERATION POLYPROPYLENEIMINE DENDRIMER PPI-G4-OS-MAL-III - The application of maltotriose-coated 4th generation polypropyleneimine dendrimer PPI-G4-OS-Mal-III containing 25-45% of peripheral amines groups coated with maltotriose particles to make a drug for treating neoplastic proliferation diseases, particularly chronic lymphocytic leukemia. | 10-29-2015 |
| 20150306236 | BOLAAMPHIPHILIC COMPOUNDS, COMPOSITIONS AND USES THEREOF - Bolaamphiphilic compounds are provided according to formula I: | 10-29-2015 |
| 20150320692 | APPLICATION OF MALTOTRIOSE-COATED 4TH GENERATION POLYPROPYLENEIMINE DENDRIMER PPI-G4-DS-MAL-III - The application of maltotriose-coated 4th generation polypropyleneimine dendrimer PPI-G4-DS-Mal-III containing 80-95% of peripherial amines groups coated with maltotriose particles to make a drug for treating neoplastic proliferation diseases, particularly chronic lymphocytic leukemia. | 11-12-2015 |
| 20150322173 | PROCESS FOR THE PREPARATION OF POLYMERIC BIOSURFACTANTS - The present invention relates to polymeric biosurfactants isolated from two bacterial strains of | 11-12-2015 |
| 20150328250 | Animal Food Composition and Method - The present invention provides an animal food composition comprising a food component, chitosan and a benefit agent, wherein the benefit agent forms a complex with the chitosan and wherein the chitosan-benefit agent complex forms a gel at a pH in the range from about 7 to about 8. Methods for delivery of a benefit agent and for treating an oral cavity condition wherein the benefit agent is a therapeutic agent are disclosed. | 11-19-2015 |
| 20150351388 | COMPOSITIONS AND METHODS FOR INHIBITING POTATO PATHOGENS - This application relates to compositions and methods for inhibiting the growth of potato pathogens preventing disease during post-harvest storage and processing conditions. | 12-10-2015 |
| 20150352056 | MICROENCAPSULATION TECHNIQUE AND PRODUCTS THEREOF - Inside-out gelation process to generate hydrogel microcapsules (aka microbeads). Methods of encapsulating biological material in the microbead 3-dimensional hydrogel matrix are described herein. The process generally comprises formation of a mixture of a hydrogel precursor compound, an optional biological material, and a divalent cation. The mixture is then combined with alginate, to generate an alginate shell around droplets of the mixture, followed by gelation of the hydrogel precursor core, and removal of the temporary alginate shell to yield self-sustaining microbeads. | 12-10-2015 |
| 20150359885 | THERMAL THERAPEUTIC REAGENT - A thermal therapeutic reagent is provided. The thermal therapeutic reagent comprises a plurality of magnetic nanoparticles, a plurality of surfactants coating on the magnetic nanoparticles respectively, and a polar magnetic fluid for delivering the magnetic nanoparticles to a target site. Wherein, the magnetic nanoparticles are capable of being activated under a magnetic field applied at the target site. Another thermal therapeutic reagent comprising a non-polar magnetic fluid is also provided. | 12-17-2015 |
| 20160022595 | BIOADHESIVE AND BIODEGRADABLE AND FORMULATIONS THAT PROVIDE SUSTAINED RELEASE OF ANTIMICROBIALS, BACTERIOPHAGES AND ANTI-INFLAMMATORY MEDICATIONS FOR INACTIVATION OF BIOFILMS AND THE TREATMENT OF RHINOSINUSITIS AND OTHER INFECTIONS - Described is a composition comprising one or more active ingredients coated, dispersed, or dissolved with a mucoadhesive polymer. Although subject to multiple uses, the composition, in some embodiments, is usable for treating rhinosinusitis. | 01-28-2016 |
| 20160030360 | MODIFIED ALGINATES FOR ANTI-FIBROTIC MATERIALS AND APPLICATIONS - Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body. | 02-04-2016 |
| 20160038432 | ENCAPSULATION OF MESSENGER RNA - The present invention provides an improved process for lipid nanoparticle formulation and mRNA encapsulation. In some embodiments, the present invention provides a process of encapsulating messenger RNA (mRNA) in lipid nanoparticles comprising a step of mixing a mRNA solution and a lipid solution, wherein the mRNA solution and/or the lipid solution are at a pre-determined temperature greater than ambient temperature. | 02-11-2016 |
| 20160051594 | Therapeutic Compositions and Uses Thereof - The invention provides pharmaceutical compositions, including anti-gastrointestinal cancer compositions, containing propolis and cyclodextrin. Methods of using such compositions, in particular in the treatment or prevention of gastrointestinal cancers, and in the resenitisation of gastrointestinal cancers to therapy, are also provided. | 02-25-2016 |
| 20160053029 | ETHYLSULFONATED HYALURONIC ACID BIOPOLYMERS AND METHODS OF USE THEREOF - The present disclosure provides methods for sulfonation of hyaluronic acid. The present disclosure provides sulfonated hyaluronic acid, and compositions, including pharmaceutical compositions, comprising the sulfonated hyaluronic acid. The present disclosure provides implantable materials and drug delivery compositions comprising a subject sulfonated hyaluronic acid. | 02-25-2016 |
| 20160081940 | PROBIOTIC LIQUID FOOD PRODUCTS FOR INFANTS - Provided are heat-processed or heat-processible health food products beneficially affecting the consumer's intestinal microbial balance. The food products are particularly liquid-based products which comprise a probiotic component capable of resisting heat and humidity. | 03-24-2016 |
| 20160138028 | GLUCAN-ENCAPSULATED SIRNA FOR TREATING TYPE 2 DIABETES MELLITUS - Compositions comprising glucan-encapsulated siRNA directed against a region of the gene encoding the human CB1 receptor for use in the treatment of type 2 diabetes mellitus in a human subject. Additionally, methods for treating type 2 diabetes mellitus in a subject, comprising administering to the subject a composition comprising glucan-encapsulated siRNA directed against the CB1 receptor. | 05-19-2016 |
| 20160143857 | HYBRID ALGINATE-SILICA BEADS AND METHOD FOR OBTAINING THEM - A hybrid silica bead having a millimeter scaled-size is adapted for the entrapment of a component or a bioactive substance. The bead is formed of a porous core including a hybrid alginate-silica and an external porous layer having silica and a silica concentrator. A one-pot process prepares hybrid beads for use of the beads for the entrapment of a component or a bioactive substance. | 05-26-2016 |
| 20160143943 | Core-Shell Crosslinked Hyaluronic Acid Gel Particles, Production Method for Same, and Medical Material - A core-shell gel particle of the invention contains a crosslinked hyaluronic acid, has a higher equilibrium swelling capacity at the surface than at the center, the equilibrium swelling capacity showing a change curve with an inflection point from the center to the surface, and has a probe pushing force of 20 nN or less from the surface to a depth of 800 nm. | 05-26-2016 |
| 20160151295 | ORAL PARTICULATE ANTITUMOR PREPARATION | 06-02-2016 |
| 20160374950 | NANOPARTICLE DRUG DELIVERY - Therapeutic formulations are described for use in the treatment of chronic obstructive pulmonary disease, bronchial asthma, cystic fibrosis, chlorine inhalation, influenza and acute myocardial infarction. The formulations comprise polymeric nanoparticles or polymeric nanoparticles encapsulated within cross-linked polymeric hydrogel microparticles, wherein the polymeric nanoparticles carry a therapeutic agent suitable for treatment of chronic obstructive pulmonary disease, bronchial asthma, cystic fibrosis, chlorine inhalation, influenza, acute myocardial infarction and heart failure. Preferred formulations are inhalable, dry powder therapeutic formulations, which are able to swell on administration to the lungs of a patient. | 12-29-2016 |
| 20180021368 | BOLAAMPHIPHILIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | 01-25-2018 |
| 20220133725 | PULSE DOSING REGIMEN AND METHODS OF TREATMENT - A novel dosing regimen for erlotinib or a pharmaceutically acceptable salt thereof is described herein. The dosing regimen demonstrates impressive control of central nervous system disease, which is better than that reported with standard dose erlotinib. The use of the novel dosing regimen for treating patients in need thereof, including for controlling formation of metastatic brain, leptomeninges, or CNS lesions in a patient with non-small cell lung cancer (NSCLC) that harbors epidermal growth factor receptor (EGFR) mutation with or without pre-existing brain metastases, is also described herein. | 05-05-2022 |
